FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
FibroGen (FGEN) reported a Q3 loss of $0.17 per share, which is better than the Zacks Consensus Estimate of a $0.38 loss. This is an improvement from the $0.52 loss per share reported a year ago.
November 13, 2024 | 12:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FibroGen reported a Q3 loss of $0.17 per share, better than the expected $0.38 loss, and an improvement from last year's $0.52 loss.
FibroGen's reported loss per share was significantly better than both the consensus estimate and the previous year's loss, indicating positive financial performance. This is likely to have a positive short-term impact on the stock price as it shows the company is performing better than expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100